Sorrento Therapeutics (SRNE)
(Delayed Data from OTC)
$0.01 USD
0.00 (-22.07%)
Updated May 31, 2024 03:53 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Sorrento Therapeutics, Inc. [SRNE]
Reports for Purchase
Showing records 121 - 140 ( 186 total )
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sorrento''s Scintilla Notches Positive SP-102 Clinical Data; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sorrento''s Scintilla Notches Positive SP-102 Clinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ZTilido Adhesion Superiority; Celularity Assets Contributed; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ZTilido Adhesion Superiority; Celularity Assets Contributed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage due to the departure of the covering analyst. Shares will remain Under Review
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains Undervalued; Lowering Price Target to $20
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains Undervalued; Lowering Price Target to $20
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage to Mark Breidenbach, Ph.D., due to the departure of the covering analyst and placing shares Under Review.
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ZTLido Pivotal Bioequivalence Study Hits; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging CAR-T Preclinical Data Set IND Stage
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Innovations in Oncology Corporate Access Day Recap
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; Plenty Going On and Increasing Focus; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continuing Chess Moves; TNK Lending a Hand; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Healthcare Monthly Catalyst Tracker; Does The Election Matter to Biotech?
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J